INBS · Company research
Intelligent Bio Solutions Inc. Common Stock (INBS): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
15records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| INBS Stock Reverses Early Gains After First Shipment of Drug Screening Readers Under Syrma Johari MedTech Partnership - Stocktwits | INBS Stock Reverses Early Gains After First Shipment of Drug Screening Readers Under Syrma Johari MedTech Partnership Stocktwits | View source ↗ | Stocktwits | Oct 8, 2026 | neutral | 0 | 0.6 |
| Intelligent Bio Solutions (NasdaqCM:INBS) Stock Price - Simply Wall Street | Intelligent Bio Solutions (NasdaqCM:INBS) Stock Price Simply Wall Street | View source ↗ | Simply Wall Street | Sep 25, 2026 | neutral | 0 | 0.6 |
| INTELLIGENT BIO SOLUTIONS INC. SEC Filing (Sep 24, 2026) | INBS EFFECT - Stock Titan | INTELLIGENT BIO SOLUTIONS INC. SEC Filing (Sep 24, 2026) | INBS EFFECT Stock Titan | View source ↗ | Stock Titan | Sep 24, 2026 | neutral | 0 | 0.6 |
| Intelligent Bio Solutions Inc. Stock Grades | INBS - Barron's | Intelligent Bio Solutions Inc. Stock Grades | INBS Barron's | View source ↗ | Barron's | Sep 15, 2026 | neutral | 0 | 0.6 |
| INBS Stock Draws Traders As FDA 510(k) Milestones Pile Up - StocksToTrade | INBS Stock Draws Traders As FDA 510(k) Milestones Pile Up StocksToTrade | View source ↗ | StocksToTrade | Sep 1, 2026 | neutral | 0 | 0.6 |
| INBS Stock Steadies As FDA Milestones And Revenue Growth Stack Up - Timothy Sykes | INBS Stock Steadies As FDA Milestones And Revenue Growth Stack Up Timothy Sykes | View source ↗ | Timothy Sykes | Sep 1, 2026 | neutral | 0 | 0.6 |
| Intelligent Bio Solutions Revenue Rises 38% to $4.2 Million in Fiscal 2026 - Quiver Quantitative | Intelligent Bio Solutions Revenue Rises 38% to $4.2 Million in Fiscal 2026 Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 19, 2026 | neutral | 0 | 0.6 |
| Intelligent Bio Solutions Revenue Rises 38% to $4.2 Million in Fiscal 2026 - Moomoo | Intelligent Bio Solutions Revenue Rises 38% to $4.2 Million in Fiscal 2026 Moomoo | View source ↗ | Moomoo | Aug 19, 2026 | neutral | 0 | 0.6 |
| A Fingerprint Drug Test Aligns With the FDA's New Regulation—What's Next? - Stock Titan | A Fingerprint Drug Test Aligns With the FDA's New Regulation—What's Next? Stock Titan | View source ↗ | Stock Titan | Aug 17, 2026 | neutral | 0 | 0.6 |
| Intelligent Bio Solutions' Fingerprint Drug Study Enrolled 135 - Stock Titan | Intelligent Bio Solutions' Fingerprint Drug Study Enrolled 135 Stock Titan | View source ↗ | Stock Titan | Aug 11, 2026 | neutral | 0 | 0.6 |
| INBS Forecast — Price Target — Prediction for 2027 - TradingView | INBS Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 27, 2026 | neutral | 0 | 0.6 |
| INBS Stock Gains Triple-Digit Rally So Far In January: What’s Driving The Surge And What Traders Are Saying - Stocktwits | INBS Stock Gains Triple-Digit Rally So Far In January: What’s Driving The Surge And What Traders Are Saying Stocktwits | View source ↗ | Stocktwits | Mar 5, 2026 | neutral | 0 | 0.6 |
| Why Is INBS Stock Rising Today? - Stocktwits | Why Is INBS Stock Rising Today? Stocktwits | View source ↗ | Stocktwits | Mar 5, 2026 | neutral | 0 | 0.6 |
| INBS Stock Surges 132.4% on New Manufacturing Partnership - Yahoo Finance | INBS Stock Surges 132.4% on New Manufacturing Partnership Yahoo Finance | View source ↗ | Yahoo Finance | Jan 2, 2026 | neutral | 0 | 0.6 |
| Should I buy INTLGNT BIO SOL (INBS) - Zacks Investment Research | Should I buy INTLGNT BIO SOL (INBS) Zacks Investment Research | View source ↗ | Zacks Investment Research | Jan 2, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.